LivaNova Plc

As of August 13, 2025, LivaNova Plc's technical trend has shifted to bullish, supported by positive indicators like a bullish MACD and moving averages, despite underperforming the S&P 500 over the long term but outperforming year-to-date.

As of May 7, 2025, LivaNova Plc is considered overvalued and risky due to its negative P/E ratio, poor returns on capital, and underperformance compared to peers and the S&P 500.

As of May 7, 2025, LivaNova Plc is considered overvalued and risky due to negative financial metrics, including a P/E ratio of -9.23 and a one-year stock return of -18.86%, significantly underperforming the S&P 500's 10.26% return.

As of May 7, 2025, the market trend is mildly bearish, influenced by daily moving averages and monthly MACD indicating bearish sentiment, while weekly indicators show short-term strength, resulting in a neutral to mildly bearish outlook overall.

As of March 2022, the management team of LivaNova Plc includes Mr. Daniel Moore (Independent Chairman), Mr. Damien McDonald (CEO), and several Independent Directors: Mr. Todd Schermerhorn, Mr. Francesco Bianchi, Mr. William Kozy, Mr. Alfred Novak, and Dr. Sharon O'Kane. They oversee the company's strategic direction and governance.

LivaNova Plc is a small-cap medical device company focused on therapeutic solutions in the Pharmaceuticals & Biotechnology industry, with recent net sales of $317 million and a net loss of $327 million. The company has a market cap of $2.44 billion and does not currently pay dividends.

As of Jun 18, LivaNova Plc has a market capitalization of 2,440.86 million, with net sales of 1,275.35 million and a net profit of -222.14 million over the latest four quarters.